研究单位：[1]Affiliated Cancer Hospital, Sun Yat-sen University[2]Peking University Cancer Hospital & Institute[3]Shanghai Jiaolian Drug Research and Development Co., Ltd[4]Shanghai Pharmaceuticals Holding Co., Ltd[5]Affiliated Cancer Hospital, Sun Yat-sen University,Guangzhou,Guangdong,China,510060[6]Guangxi Medical University Cancer Hospital,Nanning,Guangxi,China,530021[7]Hainan cancer Hospital,Haikou,Hainan,China,570312[8]Xiangyang Central Hospital,Xiangyang,Hubei,China,441021[9]Huai'an First People''s Hospital,Huai''an,Jiangsu,China,223300[10]Sichuan Cancer Hospital,Chengdu,Sichuan,China,610041[11]The second people''s hospital of neijiang,Neijiang,Sichuan,China,641199[12]Yunnan Cancer Hospital,Kunming,Yunnan,China,650118[13]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China,310005[14]Peking University Cancer Hospital,Beijing,China,100142[15]Tianjin medical university cancer institute&hospital,Tianjin,China,300060
研究目的：
This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic triple negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).
